2:45 PM - 3:00 PM (PDT), Monday, June 13, 2022
Reglagene is an oncology biotechnology company focused on developing novel medicines for difficult to treat and metastatic cancers. For example, only 4 of the 217 FDA approved cancer medicines are indicated for high-grade glioma (HGG). The best of the four, temozolomide, only extends life by 2.5 months. Cancer medicines struggle to pass into the brain, and the ones that do are toxic and ineffective. This forces patients to choose between palliative care and brief extended survival with major loss of their quality of life. The team at Reglagene is combating this unmet medical need by developing a therapeutically effective, orally administered, blood-brain barrier penetrant cancer medicine aiming to extend life and the improve the quality of life of those suffering from HGG. Although, the clinical relevance of Reglagene’s cancer medicine doesn’t end with HGG. We have shown a broad range of efficacy in multiple cancers that frequently metastasize to the brain.
Company Type:
Privately Funded Company
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
RHI 629: CNS Cancers
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):